| P50 | author | Dagmar Tapon | Q57529372 |
| P2860 | cites work | ACOG Practice Bulletin No. 88, December 2007. Invasive prenatal testing for aneuploidy | Q80138010 |
| | First-trimester screening for Down syndrome with ductus venosus Doppler studies in addition to nuchal translucency and serum markers | Q80406837 |
| | First-trimester nasal bone evaluation for aneuploidy in the general population | Q81079339 |
| | Stepwise sequential screening for fetal aneuploidy | Q81160718 |
| | Accepting or declining the offer of prenatal screening for congenital defects: test uptake and women's reasons | Q81301934 |
| | Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening | Q81450492 |
| | Postnatal support for mothers of children with Down syndrome | Q81728614 |
| | Screening for Down syndrome: practice patterns and knowledge of obstetricians and gynecologists | Q82176633 |
| | Prenatal screening for Down's syndrome | Q83354109 |
| | ACOG Practice Bulletin No. 77: Screening for Fetal Chromosomal Abnormalities | Q22242787 |
| | Ethical considerations of early (first vs. second trimester) risk assessment disclosure for trisomy 21 and patient choice in screening versus diagnostic testing | Q22252949 |
| | Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood | Q24657306 |
| | Trisomy recurrence: a reconsideration based on North American data | Q30943096 |
| | Recurrences of free trisomy 21: analysis of data from the National Down Syndrome Cytogenetic Register. | Q31011844 |
| | Diagnostic mid trimester amniocentesis: how safe? | Q31108820 |
| | Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection | Q33268343 |
| | Fetal cells in the maternal circulation: feasibility for prenatal diagnosis | Q33650187 |
| | Termination rates after prenatal diagnosis of Down syndrome, spina bifida, anencephaly, and Turner and Klinefelter syndromes: a systematic literature review. European Concerted Action: DADA (Decision-making After the Diagnosis of a fetal Abnormality | Q33751909 |
| | Third trimester abortion: is compassion enough? | Q33869421 |
| | Second-trimester ultrasound to detect fetuses with Down syndrome: a meta-analysis | Q33935082 |
| | Multicultural education and genetic counseling | Q34190548 |
| | Randomised controlled trial of genetic amniocentesis in 4606 low-risk women | Q34385464 |
| | Trends and geographic inequalities in the prevalence of Down syndrome in Europe, 1980-1999. | Q34493467 |
| | Maternal age-specific fetal loss rates in Down syndrome pregnancies | Q34516883 |
| | Pregnancy loss rates after midtrimester amniocentesis | Q34578193 |
| | First- and second-trimester evaluation of risk for Down syndrome | Q34643774 |
| | First trimester diagnosis and screening for fetal aneuploidy | Q35034029 |
| | Socioeconomic and state-level differences in prenatal diagnosis and live birth prevalence of Down's syndrome in the United States. | Q35669244 |
| | Genetic amniocentesis complications: is the incidence overrated? | Q35792768 |
| | First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome | Q35822399 |
| | A population-based evaluation of the impact of antenatal screening for Down's syndrome in France, 1981-2000. | Q35846459 |
| | Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review | Q35857896 |
| | Practitioner review: stress intervention for parents of children with intellectual disabilities | Q35917679 |
| | Does labeling prenatal screening test results as negative or positive affect a woman's responses? | Q36372717 |
| | The role of the second trimester genetic sonogram in screening for fetal Down syndrome | Q36419919 |
| | A new definition of Genetic Counseling: National Society of Genetic Counselors' Task Force report | Q36500217 |
| | Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down's syndrome | Q36591795 |
| | Informed consent: attitudes, knowledge and information concerning prenatal examinations | Q36721061 |
| | Rapid detection of trisomy 21 by quantitative PCR. | Q36765870 |
| | Presence of fetal DNA in maternal plasma and serum | Q57075132 |
| | Ethnicity, sex, and the incidence of congenital heart defects: a report from the National Down Syndrome Project | Q57315750 |
| | First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS) | Q57839618 |
| | Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening | Q57917224 |
| | Cross-trimester marker ratios in prenatal screening for Down syndrome | Q58133821 |
| | Reporting Down syndrome screening results: women's understanding of risk | Q59236352 |
| | Are pregnant women making informed choices about prenatal screening? | Q64904746 |
| | A randomized comparison of transcervical and transabdominal chorionic-villus sampling. The U.S. National Institute of Child Health and Human Development Chorionic-Villus Sampling and Amniocentesis Study Group | Q68228475 |
| | Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome | Q69029876 |
| | A sensitive enzyme immunoassay for pregnancy-associated plasma protein A (PAPP-A): a possible first trimester method of screening for Down syndrome and other trisomies | Q71598362 |
| | An association between low maternal serum α-fetoprotein and fetal chromosomal abnormalities | Q72729435 |
| | Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome | Q72730932 |
| | Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy | Q72772971 |
| | Down's syndrome screening in the UK in 1998 | Q73081342 |
| | Longitudinal effects of an early family intervention programme on the adaptation of parents of children with a disability | Q73214703 |
| | Placental and maternal serum inhibin-A and activin-A levels in Down's syndrome pregnancies | Q73423941 |
| | The impact of maternal serum screening on the birth prevalence of Down's syndrome and the use of amniocentesis and chorionic villus sampling in South Australia | Q73471975 |
| | Intra- and interoperator variability in fetal nasal bone assessment at 11-14 weeks of gestation | Q73775136 |
| | The value of screening for Down's syndrome in a socioeconomically deprived area with a high ethnic population | Q77327722 |
| | The reasons for termination of pregnancy in the third trimester | Q78059778 |
| | Antenatal Down syndrome screening in the United States in 2001: a survey of maternal-fetal medicine specialists | Q78535837 |
| | ACOG Committee Opinion No. 360: Sex selection | Q79701094 |
| | Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review | Q36927303 |
| | SAFE--the Special Non-invasive Advances in Fetal and Neonatal Evaluation Network: aims and achievements | Q37072636 |
| | Ethical aspects arising from non-invasive fetal diagnosis | Q37075330 |
| | Non-invasive fetal sex determination: impact on clinical practice | Q37075333 |
| | Comparison of different strategies in prenatal screening for Down's syndrome: cost effectiveness analysis of computer simulation | Q37104743 |
| | The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis | Q37306246 |
| | Psychological consequences for parents of false negative results on prenatal screening for Down's syndrome: retrospective interview study | Q37309125 |
| | 'Balance' is in the eye of the beholder: providing information to support informed choices in antenatal screening via Antenatal Screening Web Resource | Q37332154 |
| | What I wish I knew then...reflections from personal experiences in counseling about Down syndrome | Q39273431 |
| | Diagnostic use of meternal serum alpha-fetoprotein levels | Q39363813 |
| | Screening for Down syndrome: changing practice of obstetricians | Q39992814 |
| | Pregnant women's responses to information about an increased risk of carrying a baby with Down syndrome | Q40348290 |
| | A comparison of the impact of screen-positive results obtained from ultrasound and biochemical screening for Down syndrome in the first trimester: a pilot study | Q40507910 |
| | Patients' understanding of medical risks: implications for genetic counseling | Q41670962 |
| | Prenatally diagnosed Down syndrome: mothers who continued their pregnancies evaluate their health care providers | Q42649338 |
| | The influence of risk estimates obtained from maternal serum screening on amniocentesis rates | Q43934142 |
| | Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities | Q44259917 |
| | An evaluation of the decision-making process regarding amniocentesis following a screen-positive maternal serum screen result | Q44855360 |
| | Repeated measures screening for Down's Syndrome | Q45232979 |
| | Genetic sonography after first-trimester Down syndrome screening | Q45305102 |
| | Social and familial context of prenatal genetic testing decisions: Are there racial/ethnic differences? | Q46006503 |
| | Perceived risk of prenatal diagnostic procedure-related miscarriage and Down syndrome among pregnant women. | Q46008068 |
| | Second trimester prenatal ultrasound for the detection of pregnancies at increased risk of Down syndrome. | Q46040196 |
| | Routine ultrasonography compared with maternal serum alpha-fetoprotein for neural tube defect screening. | Q46303467 |
| | Late-term abortion | Q46357665 |
| | First-trimester or second-trimester screening, or both, for Down's syndrome | Q46799629 |
| | Procedure-related miscarriages and Down syndrome-affected births: implications for prenatal testing based on women's preferences | Q46840808 |
| | Cost utility of prenatal diagnosis and the risk-based threshold | Q46843858 |
| | Women and health care professionals' preferences for Down's Syndrome screening tests: a conjoint analysis study | Q47307138 |
| | SURUSS in perspective | Q47339084 |
| | The relative effects of paternal and maternal age in mongolism. 1933. | Q48488338 |
| | An offer you can't refuse? Ethical implications of non-invasive prenatal diagnosis | Q49161578 |
| | Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level | Q50148910 |
| | Anxiety and prenatal testing: do women with soft ultrasound findings have increased anxiety compared to women with other indications for testing? | Q50873982 |
| | Psychological variables as correlates of adjustment in mothers of children with intellectual disabilities: cross-sectional and longitudinal relationships. | Q50876820 |
| | Down's syndrome: cost, quality and value of life. | Q51064306 |
| | The adaptation of parents to the birth of an infant with a congenital malformation: a hypothetical model | Q51296837 |
| | Antenatal screening for Down's syndrome using the Integrated test at two London hospitals. | Q51836257 |
| | Health of children 3 to 17 years of age with Down syndrome in the 1997-2005 national health interview survey. | Q51872939 |
| | Long-term psychological consequences of pregnancy termination for fetal abnormality: a cross-sectional study. | Q51931874 |
| | Abortion after 24 weeks. | Q52002366 |
| | Early detection of cell-free fetal DNA in maternal plasma. | Q53576548 |
| | Down syndrome births in the United States from 1989 to 2001. | Q54575603 |
| | Absence of nasal bone in fetuses with trisomy 21 at 11–14 weeks of gestation: an observational study | Q56764725 |
| | Will the introduction of non-invasive prenatal diagnostic testing erode informed choices? An experimental study of health care professionals | Q56780865 |
| P433 | issue | 2 | |
| P921 | main subject | Down syndrome | Q47715 |
| P304 | page(s) | 112-130 | |
| P577 | publication date | 2009-11-03 | |
| P1433 | published in | Journal of Genetic Counseling | Q6295247 |
| P1476 | title | Prenatal testing for Down syndrome: comparison of screening practices in the UK and USA | |
| P478 | volume | 19 | |